Global biomedical sciences companies invested more than $500.0 million in Singapore in the year 2008. This rides on the nation's strong scientific fundamentals, with biomedical sciences R&D expenditure exceeding $760.0 million in 2007. The continued confidence in Singapore points to the city-state's attractive investment environment, as companies look to the fast-growing Asian market to fuel their growth. As a leading bio-cluster in Asia, Singapore provides access to global talent, world-class scientific and clinical excellence, as well as excellent connectivity to key regional markets.
Expanding base of research investments
A growing base of more than 50 global pharmaceutical, biotechnology and medical technology companies are carrying out R&D in Singapore, alongside 30 public-sector research and medical institutes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze